Argenica Therapeutics (ASX: AGN) chief executive officer Dr Liz Dallimore joins Small Caps to discuss the development pathway of the company's lead drug candidate ARG-007. The biotech has developed unique neuroprotective technology to reduce brain cell death following stroke and other brain injuries and has begun the preliminary work required for an upcoming phase one clinical trial. Argenica describes ARG-007 as a simple, non-disruptive intravenous injection that works to protect the brain against the damaging effects of stroke, extend the treatment window for stroke patients, reduce special care requirements and intensive rehabilitation time, and reduce hospitalisation time and post-care costs. The recently listed company raised $7 million in its initial public offering with funds primarily going towards pre-clinical and product development activities, safety assessments, regulatory approval preparation and intellectual property protection.

Articles:

https://smallcaps.com.au/argenica-therapeutics-positive-pre-clinical-results-stroke-drug-arg-007-hie/

https://smallcaps.com.au/argenica-therapeutics-start-phase-1-clinical-trials-early-next-year/

More company information:

https://smallcaps.com.au/stocks/AGN/